Mitochondrial DNA Modification via MTS-NES Fusion Polypeptide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering DNA-binding polypeptides to mitochondria are inefficient, particularly for polypeptides with strong nuclear localization, and existing technologies struggle to modify mitochondrial DNA effectively for treating genetic disorders.
Innovation Solution
A nucleic acid construct comprising a coding sequence for a DNA-binding polypeptide fused with a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), along with an effector molecule like a restriction endonuclease, is used to deliver and modify mitochondrial DNA, allowing for site-specific modification of mtDNA associated with diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a mitochondrial targeting sequence (MTS) is used to deliver DNA-binding polypeptides to mitochondria, then mitochondrial delivery is attempted, but polypeptides with strong nuclear localization signals are resistant to delivery and accumulate in the nucleus instead
Solution Approach 1:
The targeting system is divided into separate functional modules: an N-terminal mitochondrial targeting sequence (MTS) for mitochondrial import, and a C-terminal nuclear export signal (NES) for nuclear export. This segmentation allows each module to perform its specific function independently, ensuring that DNA-binding polypeptides are delivered to mitochondria rather than accumulating in the nucleus.
Solution Approach 2:
Different regions of the fusion polypeptide are assigned different functional properties: the N-terminal MTS region provides mitochondrial targeting capability, while the C-terminal NES region provides nuclear export functionality. This local differentiation of function ensures that the polypeptide is directed to the correct cellular compartment.
2Reliability
If standard gene therapy approaches are used to deliver exogenous DNA into mitochondria, then DNA delivery is attempted, but heritable modification remains problematic and inefficient
Solution Approach 1:
A fusion polypeptide acts as an intermediary carrier that shuttles DNA-binding polypeptides across the mitochondrial membranes. The fusion polypeptide includes an MTS for mitochondrial import and an NES for nuclear export, creating a functional mediator that enables efficient delivery of therapeutic agents to mitochondria while avoiding the problems of standard DNA delivery approaches.
3Adaptability or versatility
If DNA-binding polypeptides are delivered to mitochondria for site-specific modification, then therapeutic potential is increased, but delivery efficiency for polypeptides with strong nuclear localization is poor
Solution Approach 1:
The mitochondrial targeting sequence (MTS) and nuclear export signal (NES) are merged into a single fusion polypeptide construct with the DNA-binding polypeptide. This combination ensures that the polypeptide is imported into mitochondria via the MTS and prevents nuclear accumulation via the NES, thereby improving delivery efficiency for polypeptides that would otherwise have strong nuclear localization signals.
Data Source
AI summary
Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA.